Structural Heart

This structural heart channel includes news, videos, podcasts and other content related to diagnosis and treatment of structural heart disease. Topics covered include heart valve repair and replacement, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and closing holes in the heart using, including occlusion of atrial septal defects (ASDs), ventricular septal defects (VSDs) and patent foramen ovales (PFOs).

Two of the top technology headlines this past month was the FDA clearance of the Abbott Portico transcatheter aortic valve replacement (TAVR) device, and the first women to receive a Carmat artificial heart.

Feature | BY Dave Fornell, DAIC Editor

October 6, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

October 06, 2021

The Abbott Amplatzer Talisman PFO Occlusion System is designed to treat people with a patent foramen ovale (PFO). The small opening between the upper chambers of the heart can increase the risk of recurrent ischemic stroke.

News | Structural Heart Occluders

FDA Clears Abbott Amplatzer Talisman PFO Occluder

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

October 04, 2021

Videos | Stem Cell Therapies

VIDEO: Engineered Heart Tissue Aids Research With a Heart in a Dish System

Mechanical engineering Professor Nathan Sniadecki, associate chair for research and infrastructure, mechanical ...

October 04, 2021

Videos | Structural Heart

VIDEO: Roles of the Melody and Harmony Transcatheter Pulmonary Valves in Congenital Heart Disease

Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, and principle investigator of the Medtronic ...

September 28, 2021

Illustration of the Watchman transcatheter left atrial appendage (LAA) occluder being deployed into the LAA. FDA is concerned about higher rates of LAA occlusion complications in women compared to men, prompting the FDA to send a letter to providers warning them on possible poor outcomes.

Feature | Left Atrial Appendage (LAA) Occluders

FDA Concerned About Higher Rates of LAA Occlusion Complications in Women

September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly ...

September 27, 2021

Videos | Structural Heart

VIDEO: Abbott Structural Heart Technology Advances in 2021

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, explains the latest advances in Abbott ...

September 20, 2021

The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Feature | Structural Heart Occluders | By Dave Fornell, Editor

FDA Clears Abbott Portico TAVR System to Treat Aortic Valve Disease

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

September 20, 2021

Videos | Congenital Heart

VIDEO: The Heart Team Approach in Congenital Structural Heart Interventions

Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, explains the importance of the heart team ...

September 15, 2021

Non-invasive evaluation of heart valves using echocardiography first, and other cardiac imaging techniques when needed, is the key evaluation of heart valves in the new ESC and European Association for Cardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular heart disease. Photo by Dave Fornell.

News | Structural Heart

New European Guidelines on Valvular Heart Disease Published

September 13, 2021 — The European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery ...

September 13, 2021

The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

News | Antiplatelet and Anticoagulation Therapies

Edoxaban May Be Effective Treatment for Atrial Fibrillation After TAVR

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

September 01, 2021

News | Left Atrial Appendage (LAA) Occluders

Abbott Amplatzer Amulet LAA Occluder Offers Superior Closure Compared to Watchman

August 31, 2021 — Late-breaking data from a head-to-head clinical trial of the Amulet Left Atrial Appendage (LAA) ...

August 31, 2021

The Abbott Amplatzer Amulet left atrial appendage (LAA) transcatheter occlusion device. It received FDA clearance in August 2021. #LAA

News | Left Atrial Appendage (LAA) Occluders

FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation

August 16, 2021 — The U.S. Food and Drug Administration (FDA) approved Abbott's Amplatzer Amulet Left Atrial Appendage ...

August 16, 2021

Schematic illustration of a pre-vascularized stem cell patch having multiple stem cell-laden bio-inks to encorage heart cell regrowth at infarct areas. With permission from Elsevier. Read the original article.Jinah Jang, Reprinted from Biomaterials, Vol 112, Jinah Jang et al., 3D printed complex tissue construct using stem cell-laden decellularized extracellular matrix bioinks for cardiac repair, Pages 264-274, Copyright (2017),

News | Medical 3-D Printing

Bioprinted 3D Cardiac Patches Could Reverse Scar Formation, Promote Myocardial Regeneration After Heart Attacks

July 27, 2021 -- Cardiovascular diseases account for 32% of global deaths. Myocardial infarction, or heart attacks, play ...

July 27, 2021

Leveraging Vivasure Medical’s PerQseal vascular closure device technology, PerQseal Blue consists of an intravascular patch designed to seal the vessel from the inside, returning the vein to its natural state after it dissolves over time, so no foreign bodies are left behind.

News | Vascular Closure Devices

Vivasure Medical is Developing a Sutureless Venous Closure Device for Transcatheter Valve Procedures

July 15, 2021 — Vivasure Medical announced its development program for PerQseal Blue, a sutureless and fully ...

July 15, 2021

Videos | Structural Heart

VIDEO: Acurate neo2 TAVR Valve Performs Well in Latest Trials

Doctor Andreas Ruck, interventional cardiologist and head of the mitral/tricuspid program, Karolinska University ...

July 14, 2021